Findings

What do systematic reviews say?

8 questions · 8 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 50%GRADE not reported 0 · 0%Very low 4 · 50%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

FLUPHENAZINE DECANAOTE vs FLUPHENAZINE ENANTHATE

Relapse · patients with schizophrenia

It is very uncertain whether FLUPHENAZINE DECANAOTE changes relapse compared with FLUPHENAZINE ENANTHATE (very low certainty).

1 finding from 1 review

Fluphenazine decanoate (depot) and enanthate for schizophrenia 2015 · Cochrane Headline outcomes only
RR 2.43 [0.71, 8.32]
1 study · 49 participants
Very low

FLUPHENAZINE DECANOATE vs placebo

Relapse · patients with schizophrenia

It is very uncertain whether FLUPHENAZINE DECANOATE changes relapse compared with PLACEBO (very low certainty).

1 finding from 1 review

Fluphenazine decanoate (depot) and enanthate for schizophrenia 2015 · Cochrane Headline outcomes only
RR 0.62 [0.24, 1.6]
3 studies · 196 participants
Very low

FLUPHENAZINE DECANOATE vs ORAL NEUROLEPTICS

Relapse · patients with schizophrenia

It is very uncertain whether FLUPHENAZINE DECANOATE changes relapse compared with ORAL NEUROLEPTICS (very low certainty).

1 finding from 1 review

Fluphenazine decanoate (depot) and enanthate for schizophrenia 2015 · Cochrane Headline outcomes only
RR 1.46 [0.75, 2.83]
6 studies · 419 participants
Very low

FLUPHENAZINE (ORAL) vs QUETIAPINE

Relapse · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FLUPHENAZINE (ORAL) vs placebo

Relapse · patients with schizophrenia

It is very uncertain whether ORAL FLUPHENAZINE changes global state: Relapse ‐ long termClinical judgement compared with PLACEBO (very low certainty).

1 finding from 1 review

Fluphenazine (oral) versus placebo for schizophrenia 2018 · Cochrane Headline outcomes only
RR 0.39 [0.05, 3.31]
2 studies · 86 participants
Very low

FLUPHENAZINE (ORAL) vs AMISULPRIDE

Relapse ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FLUPHENAZINE (ORAL) vs OLANZAPINE

Relapse ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FLUPHENAZINE (ORAL) vs RISPERIDONE

Relapse ‐ not reported · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Fluphenazine (oral) versus atypical antipsychotics for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found